Use of QRX-3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
NCT ID: NCT07161843
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2/PHASE3
500 participants
INTERVENTIONAL
2025-08-30
2027-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis
NCT02007889
Evaluation of Renal Damage After PCNL and ESWL Using Novel RNA Based Biomarkers
NCT05077007
Renal MR Feasibility in Renal Disease
NCT03578523
Search for New Methods to Detect Acute Renal Failure
NCT00026702
Establishing a New Ultrasound Technique to Improve Assessment of Chronic Kidney Disease.
NCT06159439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Use of QRX-3 in addition to standard therapy
QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days
QRX-3
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
control group
placebo twice daily will be given to this group in addition to standard therapy
QRX-3
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QRX-3
Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* presence of Acute renal failure
* Nephrologist diagnosis of Acute tubular necrosis or fractional excretion of sodium of \>2%
* willingness to participate
Exclusion Criteria
10 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ebima Clifford Okundaye
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ebima Clifford Okundaye
President
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Neukidney Inc
Rosharon, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.